4 withdrawn. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Withdrawn 4 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Refractory Chronic Lymphocytic Leukemia: new trials by email Literature Review of Refractory Chronic Lymphocytic Leukemia trials Research Report on Refractory Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 | |
| Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation sotrastaurin acetate, pharmacological study, laboratory biomarker analysis - Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma | Phase 2 | Withdrawn | James Blachly | 2015-03-12 | 2017-04-05 | |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment fludarabine phosphate, rituximab, bevacizumab - B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 2 | Withdrawn | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 2009-01-01 | 2015-03-06 |
Leukemia, Lymphocytic, Chronic, B-Cell (4) · Burkitt Lymphoma (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, Non-Hodgkin (2) · Blast Crisis (1) · Congenital Abnormalities (1) · Disease Progression (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Intraocular Lymphoma (1) · Leukemia, Hairy Cell (1) · Leukemia, Large Granular Lymphocytic (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Prolymphocytic (1)
Chronic Disease (4) · Disease Attributes (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Leukemia (4) · Leukemia, B-Cell (4) · Leukemia, Lymphoid (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4)
Cyclophosphamide (2) · fludarabine phosphate (2) · Bevacizumab (1) · Cord Blood Stem Cell Transplantation (1) · Flow Cytometry (1) · In Situ Hybridization, Fluorescence (1) · Mycophenolic Acid (1) · Peripheral Blood Stem Cell Transplantation (1) · Polymerase Chain Reaction (1) · Rituximab (1) · Tacrolimus (1) · Transplantation (1) · Whole-Body Irradiation (1) · fludarabine (1) · sotrastaurin (1)
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · James Blachly (1) · M.D. Anderson Cancer Center (1) · University of Medicine and Dentistry of New Jersey (1)
United States (2)
James Blachly, MD (1) · Jin S Im (1) · John Pagel (1) · Roger Strair (1)
P30CA016672 (1), P30CA072720 (1)